⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Drospirenone + ethinyl estradiol

دروسپیرنون + اتینیل استرادیول (یاسمین)

⚠ Unverified

🚻 Genito Urinary System And Sex HormonesCombined oral contraceptive

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA021098 ATC G03AA12

Market / country: 🇺🇸 USA

Yasmin (US)

🧮 Dose calculator

Disease / regimen

Contraception (combined pill) · Regimen source: FDA Yasmin · 2

⛔ One tablet daily at the same time in pack order (21 active + 7 inert). FDA Yasmin · 2

🛡️ Safety & information

Contraindications

⛔ Renal impairment; adrenal insufficiency; high risk of arterial or venous thrombosis (smokers over 35, DVT/PE history, cerebrovascular or coronary disease, etc.); breast cancer; liver disease; undiagnosed uterine bleeding; pregnancy. FDA Yasmin · 4

Warnings

• Boxed warning: smoking raises the risk of serious cardiovascular events, especially over 35. Drospirenone can raise potassium. FDA Yasmin · Boxed Warning FDA Yasmin · 5

Formulations

21 active tablets (3 mg drospirenone + 0.03 mg EE) + 7 inert — tablet 🇺🇸 USA FDA Yasmin · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Yasmin · 8.1
“Risk Summary There is no use for contraception in pregnancy; therefore, Yasmin should be discontinued during pregnancy.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Yasmin · 8.2
“Risk Summary DRSP is present in human milk.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Yasmin · 8.4
“Safety and efficacy of Yasmin has been established in women of reproductive age.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Yasmin · 8.5
“Yasmin has not been studied in postmenopausal women and is not indicated in this population.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA021098
DailyMed (FDA label)FDA Yasmin
MedlinePlus (NIH)Ethinyl Estradiol and Drosperinone (Oral Contraceptive)Ethinyl Estradiol and Norethindrone (Oral Contraceptives)
WHO ATC/DDDG03AA12
Darooyab (Iran)Drospirenone-Ethinylestradiol

🇮🇷 Registered in Iran Darooyab · G-4627/Drospirenone-Ethinylestradiol

Dosage forms with Iranian generic codes, per Darooyab.

17222 · DROSPIRENONE/ETHINYL ESTRADIOL 2/1MG TAB · قرص دروسپیرنون / اتینیل استرادیول ۲ / ۱ میلی‌گرم
14870 · DROSPIRENONE/ETHINYL ESTRADIOL 3/0.02MG TAB · قرص دروسپیرنون / اتینیل استرادیول ۳ / ۰٫۰۲ میلی‌گرم
09090 · DROSPIRENONE/ETHINYL ESTRADIOL 3/0.03MG TAB · قرص دروسپیرنون / اتینیل استرادیول ۳ / ۰٫۰۳ میلی‌گرم

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Yasmin · 3 FDA Yasmin · 2 FDA Yasmin · 4 FDA Yasmin · Boxed Warning FDA Yasmin · 5 FDA Yasmin · 8.1 FDA Yasmin · 8.2 FDA Yasmin · 8.4 FDA Yasmin · 8.5 FDA Yasmin · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-4627/Drospirenone-Ethinylestradiol
Clinical review⚠ Unverified